"Teaching" Doctors To Push Failing HPV Vaccine
"Teaching" Doctors To Push Failing HPV Vaccine &
Offering Free CME Credits
This activity is supported by an educational grant from Merck & Co., Inc.
Overview
CME
Author(s)/Faculty: Rachel N. Caskey, MD, MaPP; Kenneth A. Alexander, MD, PhD
Source: Healio - Infectious Disease Education Lab
Type: Lecture
Release Date: 2/9/2018
Credit Type: CME
Cost: Free
Articles/Items: 5
Expiration Date: 2/8/2019
Number of Credits: 0.75
Provider:
This activity is supported by an educational grant from Merck & Co., Inc.
Recent recommendations from the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention suggest timing and dosage changes for the human papillomavirus (HPV) vaccine. Disease prevention remains the most important measure of long-term duration of vaccine efficacy. Concern about vaccine safety and related adverse events has been identified as an important barrier to vaccination, as well as a causative factor for low HPV-vaccination coverage. Recommendation from health care providers is one of the most consistent correlates for HPV vaccination, but efficient communication styles about its prophylaxis is suboptimal. Physicians should be knowledgeable about the recent ACIP recommendations, as well as the safety and efficacy associated with each of the HPV vaccines, to select the most appropriate prophylaxis for their patients. In this CME activity, expert faculty will review the clinical guidelines, the advances in HPV vaccination, and the strategies to increase completion of the HPV vaccination series.
HPV Immunization: Applying Fact versus Fiction
Recent recommendations from the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention suggest timing and dosage changes for the human papillomavirus (HPV) vaccine. Disease prevention remains the most important measure of long-term duration of vaccine efficacy. Concern about vaccine safety and related adverse events has been identified as an important barrier to vaccination, as well as a causative factor for low HPV-vaccination coverage.
Recommendation from health care providers is one of the most consistent correlates for HPV vaccination, but efficient communication styles about its prophylaxis are lacking. Physicians should be knowledgeable about the recent ACIP recommendations, as well as the safety and efficacy associated with each of the HPV vaccines, to select the most appropriate prophylaxis for their patients.
In this CME activity, expert faculty will review the clinical guidelines, the advances in HPV vaccination, and the strategies to increase completion of the HPV vaccination series.
Activity Chair:
Kenneth A. Alexander, MD, PhD
Chief
Division of Allergy, Immunology, Rheumatology, and Infectious Diseases
Nemours Children's Hospital
Orlando, FL
Faculty:
Rachel N. Caskey, MD, MaPP
Associate Professor of Pediatrics and Internal Medicine
University of Illinois at Chicago
Chicago, IL
This continuing medical education activity is provided by
CME Information
Provider Statement: This continuing medical education activity is provided by
.
Support Statement: This activity is supported by an educational grant from Merck & Co., Inc.
Target Audience: The intended audience for this activity is pediatricians and other health care professionals involved in the treatment of patients with HPV.
Learning Objectives: Upon successful completion of this activity, participants should be better able to:
- Evaluate the latest clinical guidelines regarding the timing of HPV immunizations in preteens and teens.
- Examine effective strategies to overcome barriers that impede successful completion of the HPV immunization series in both boys and girls.
Example of questions on pre-test...
This activity is supported by an educational grant from Merck & Co., Inc.
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release February 9, 2018 to February 8, 2019.
